Glycomine Initiates Dosing in a Global, Randomized, Placebo-Controlled Phase 2b Study of GLM101 for the Treatment of PMM2-CDGSeptember 8, 2025Read article
Leriglitazone Marketing Authorization Application submitted for treatment of cerebral adrenoleukodystrophy has been validated by European Medicines AgencySeptember 8, 2025Read article
Minoryx receives a EUR 26.9m grant within the framework of the European IPCEI Med4Cure project for the continued development of leriglitazone in lethal orphan CNS diseasesSeptember 8, 2025Read article
Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 8, 2025Read article
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business HighlightsSeptember 8, 2025Read article
Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDGJune 11, 2025Read article
Results from NEXUS interim analysis published in eClinicalMedicine, part of THE LANCET DiscoveryScienceJune 11, 2025Read article
Aura Biosciences Announces Proposed Public Offering of Common Stock and WarrantsJune 11, 2025Read article
Aura Biosciences Reports First Quarter 2025 Financial Results and Business HighlightsJune 11, 2025Read article
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of DirectorsJune 11, 2025Read article
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business HighlightsJune 11, 2025Read article
